Add to ORKGBackground: The limited data regarding treatment of inflammatory bowel disease (IBD) with anti-tumor necrosis factor antibodies in older patients suggest equal efficacy but higher morbidity and mortality compared to younger patients. This retrospective case control study aims to clarify the efficacy and safety of infliximab (IFX) in older IBD patients
Background The GEMINI trials established the efficacy of vedolizumab in moderate-to-severe inflammat...
Background: Infliximab, a chimeric anti-tumour necrosis factor monoclonal antibody with potent anti-...
The incidence and prevalence of inflammatory bowel disease (IBD) is increasing, and considering the ...
Limited data suggest anti-tumor necrosis factor (TNF) antibodies have equal efficacy but higher morb...
BACKGROUND & AIMS: Few data are available on effects of biologic therapies in patients more than 65 ...
BACKGROUND & AIMS: Few data are available on effects of biologic therapies in patients more than 65...
BackgroundThe general increased life expectancy is reflected in the age of patients with inflammator...
BACKGROUND & AIMS: Few data are available on effects of biologic therapies in patients more than 65...
BACKGROUND AND OBJECTIVE: Older people with inflammatory bowel disease (IBD) appear to have a lower...
BACKGROUND AND AIMS: There is paucity of data on safety and efficacy of anti-tumour necrosis factor ...
Purpose To assess safety and effectiveness of anti-tumor necrosis factor (anti-TNF) therapy in IBD p...
INTRODUCTION: There are limited data on comparative risk of infections with various biologic agents ...
Development and application of statistical models for medical scientific researc
Introduction: Data about the safety of vedolizumab and ustekinumab are lacking in older patients wit...
Background The GEMINI trials established the efficacy of vedolizumab in moderate-to-severe inflammat...
Background: Infliximab, a chimeric anti-tumour necrosis factor monoclonal antibody with potent anti-...
The incidence and prevalence of inflammatory bowel disease (IBD) is increasing, and considering the ...
Limited data suggest anti-tumor necrosis factor (TNF) antibodies have equal efficacy but higher morb...
BACKGROUND & AIMS: Few data are available on effects of biologic therapies in patients more than 65 ...
BACKGROUND & AIMS: Few data are available on effects of biologic therapies in patients more than 65...
BackgroundThe general increased life expectancy is reflected in the age of patients with inflammator...
BACKGROUND & AIMS: Few data are available on effects of biologic therapies in patients more than 65...
BACKGROUND AND OBJECTIVE: Older people with inflammatory bowel disease (IBD) appear to have a lower...
BACKGROUND AND AIMS: There is paucity of data on safety and efficacy of anti-tumour necrosis factor ...
Purpose To assess safety and effectiveness of anti-tumor necrosis factor (anti-TNF) therapy in IBD p...
INTRODUCTION: There are limited data on comparative risk of infections with various biologic agents ...
Development and application of statistical models for medical scientific researc
Introduction: Data about the safety of vedolizumab and ustekinumab are lacking in older patients wit...
Background The GEMINI trials established the efficacy of vedolizumab in moderate-to-severe inflammat...
Background: Infliximab, a chimeric anti-tumour necrosis factor monoclonal antibody with potent anti-...
The incidence and prevalence of inflammatory bowel disease (IBD) is increasing, and considering the ...